Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription 15.09.2025 1 Acta Psychiatr Scand 1 Am J Med Genet B Neuropsychiatr Genet 2 Br J Psychiatry 1 J Clin Psychopharmacol 2 Mol Psychiatry 1 Neuropsychopharmacology 1 Proc Natl Acad Sci U S A 1 Psychiatry Res 1 Psychol Med 9 Schizophr Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Psychiatr Scand

1. HIERONYMUS F, Hieronymus M, Sjostedt A, Nilsson S, et al
   Predicting Remission in Schizophrenia Using Machine Learning-Assessing the Impact of Sample Size and Predictor Overinclusion.
   Acta Psychiatr Scand. 2025 Sep 10. doi: 10.1111/acps.70037.
   PubMed         Abstract available
   
   

   
   Am J Med Genet B Neuropsychiatr Genet

2. GAMA-MARQUES J, Finsterer J
   Pseudo-Schizophrenia Should Always Be Considered in Genetic Studies Regarding Psychosis.
   Am J Med Genet B Neuropsychiatr Genet. 2025 Sep 9. doi: 10.1002/ajmg.b.33062.
   PubMed        
   
   

   
   Br J Psychiatry

3. PATEL R
   Cannabis and psychosis: minimising harm while maximising therapeutic potential.
   Br J Psychiatry. 2025 Sep 11:1-2. doi: 10.1192/bjp.2025.10389.
   PubMed         Abstract available
   
   
4. MONCRIEFF J, Priebe S
   The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders: commentary, Moncrieff et al.
   Br J Psychiatry. 2025 Sep 8:1-2. doi: 10.1192/bjp.2025.
   PubMed        
   
   

   
   J Clin Psychopharmacol

5. KUMAR V, Ramesh V, Manchegowda S, Krishna Prasad M, et al
   Levodopa Augmentation of Antipsychotics for Persistent Negative Symptoms in Schizophrenia: An Open-Label Study.
   J Clin Psychopharmacol. 2025 Sep 10. doi: 10.1097/JCP.0000000000002084.
   PubMed        
   
   

   
   Mol Psychiatry

6. BOJESEN KB, Ambrosen KS, Sigvard AK, Nielsen MO, et al
   Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naive psychosis patients and the association to initial treatment response.
   Mol Psychiatry. 2025 Sep 12. doi: 10.1038/s41380-025-03229.
   PubMed         Abstract available
   
   
7. LUKOW PB, Schubert JJ, Severino M, Knight SR, et al
   GABA(A) receptor availability in clinical high-risk and first-episode psychosis: a [(11)C]Ro15-4513 positron emission tomography study.
   Mol Psychiatry. 2025 Sep 6. doi: 10.1038/s41380-025-03204.
   PubMed         Abstract available
   
   

   
   Neuropsychopharmacology

8. HOLMES DR
   From psychosis to creativity: a lived experience perspective on serious mental illness symptoms.
   Neuropsychopharmacology. 2025 Sep 10. doi: 10.1038/s41386-025-02212.
   PubMed        
   
   

   
   Proc Natl Acad Sci U S A

9. MOYA R, Wang X, Tsien RW, Maurano MT, et al
   Structure of a polymorphic repeat at the CACNA1C schizophrenia locus.
   Proc Natl Acad Sci U S A. 2025;122:e2415650122.
   PubMed         Abstract available
   
   

   
   Psychiatry Res

10. PATEL SES, Haut KM, Lee H, Fisher M, et al
    Social cognition training improves recognition of individual emotions in schizophrenia disorder.
    Psychiatry Res. 2025;352:116711.
    PubMed         Abstract available
    
    

    
    Psychol Med

11. DE BEER F, de Vries E, Wijnen B, Begemann MJH, et al
    Dopamine D(2/3)R availability after discontinuation of antipsychotic treatment: a [(11)C]raclopride PET study in remitted first-episode psychosis patients.
    Psychol Med. 2025;55:e264.
    PubMed         Abstract available
    
    

    
    Schizophr Res

12. ORLOVIC I, Markos IS, Blazekovic I, Peitl V, et al
    Thalamic hyperperfusion in early schizophrenia: Associations with cognitive deficits and negative symptoms.
    Schizophr Res. 2025;285:60-69.
    PubMed         Abstract available
    
    
13. HORSDAL HT, Jensen AS, Antonsen S, Pedersen MG, et al
    Examining relationships between the Danish Composite Deprivation Index and risk of developing schizophrenia: A national multilevel analysis.
    Schizophr Res. 2025;285:52-59.
    PubMed         Abstract available
    
    
14. IVLEVA EI, Palka JM, Bobilev AM, Fang Y, et al
    Hippocampal subfield activity in schizophrenia: Effects of the disease course.
    Schizophr Res. 2025;285:39-51.
    PubMed         Abstract available
    
    
15. XU M, Gao D, Hu A, Qian H, et al
    Social isolation and its influencing factors among family caregivers of individuals with schizophrenia: A social-ecological systems theory perspective.
    Schizophr Res. 2025;285:30-38.
    PubMed         Abstract available
    
    
16. HAMMER LA, Springfield CR, Russell MT, Twilbeck B, et al
    Minority stress and schizophrenia-like experiences in sexual and gender minority adults.
    Schizophr Res. 2025;285:27-29.
    PubMed        
    
    
17. BAREIS N, Wang Y, Olfson M, Gerhard T, et al
    Machine learning for novel phenotyping in schizophrenia.
    Schizophr Res. 2025;285:19-26.
    PubMed         Abstract available
    
    
18. SU Q, Liu Y, Ji L, Sun X, et al
    The relationship between age of onset, peripheral plasma protein markers and social cognition in first-episode drug-naive schizophrenia.
    Schizophr Res. 2025;285:11-18.
    PubMed         Abstract available
    
    
19. LIU D, Choi KW, Lizano P, Yuan W, et al
    Construction of extra-large scale screening tools for risks of severe mental illnesses using real world healthcare data.
    Schizophr Res. 2025;283:59-66.
    PubMed         Abstract available
    
    
20. FASSLER L, Moritz S, Schories F, Bajbouj M, et al
    Effects of an unguided self-help intervention for distressing auditory verbal hallucinations in a heterogenous sample of voice hearers: A randomized controlled trial and explorative cluster analysis.
    Schizophr Res. 2025;283:36-47.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.